As medical device companies bring new innovations to market, navigating the complex regulatory landscape can make or break a product’s success.
From classification errors to incomplete documentation, small missteps can cause major delays, particularly when engaging with European regulators under MDR (EU) 2017/745. Understanding common pitfalls is the first step to avoiding them.
1. Underestimating classification complexity
At the earliest stage of development, an incorrect classification can derail timelines. Under the MDR, rules for classification are stricter and more nuanced than under the previous MDD. This includes software, which may now fall under high-risk classes than anticipated. Misjudging the classification of your device can lead to the wrong conformity route, inadequate clinical evidence, or even rejections at notified body level.
Early dialogue with experienced regulatory professionals can help clarify classification strategy and reduce uncertainty.
2. Failing to plan for clinical evidence requirements
The MDR has significantly raised the bar for clinical evaluation. Even legacy products must now provide robust clinical data, and equivalence is much harder to claim. Some companies still rely on outdated assumptions, expecting literature reviews or comparator data alone to suffice.
If clinical data is not proactively gathered, manufacturers may face a scramble to launch expensive new studies late in development, often under pressure from notified bodies or competent authorities.
3. Overlooking the role of the notified body
Your notified body is more than a checkpoint at the end of development. Under MDR, their involvement is earlier and more intensive, especially for higher-risk devices. Delays can occur when manufacturers submit incomplete or inconsistent documentation or fail to address notified body feedback in a timely and strategic way.
Establishing early communication, agreeing on expectations and maintaining transparency throughout the process is vital to avoiding last-minute surprises.
4. Inadequate Post-Market Surveillance planning
The MDR’s post-market obligations have expanded dramatically. A robust PMS plan is no longer optional; it must be risk-based, device-specific and integrated into your quality system from the start. Some companies treat it as a formality, only to find their technical documentation rejected for lack of detail.
In addition, the requirement to submit regular Periodic Safety Update Reports (PSURs) and proactively manage vigilance data has created a new layer of operational complexity, particularly for companies with limited regulatory capacity.
5. Treating regulatory strategy as a standalone task
Finally, regulatory affairs should never be an afterthought. It must be embedded in every stage of development, from design input through to post-market monitoring. Teams that isolate regulatory decisions from clinical, commercial or technical planning risk misalignment and missed opportunities.
An integrated strategy enables better foresight, more persuasive submissions, and ultimately faster access to the market.
Even the most innovative device can hit a wall if regulatory strategy is not prioritised early. Success under MDR depends on clarity, integration and proactive engagement